Given the relatively high prevalence of ATM mutations in prostate cancer (7), we decided to generate an additional ATM KO cell line in another prostate cancer cell line, LNCAP (Supplementary Fig. S3G), which also resulted in increased sensitivity to olaparib treatment (Supplementary Fig. S3H). Here, ATM is linked to prostate cancer.